# A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

> **NCT06307626** · PHASE3 · TERMINATED · sponsor: **argenx** · enrollment: 105 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **COMBINATION_PRODUCT:** Efgartigimod PH20 SC
- **OTHER:** Placebo PH20 SC

## Key facts

- **NCT ID:** NCT06307626
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-03-28
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-02-12
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307626, "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06307626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*